Citi lowered the firm’s price target on Mettler-Toledo (MTD) to $1,400 from $1,450 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector “remains very light,” primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm’s top pick.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTD:
- Mettler-Toledo price target raised to $1,369 from $1,362 at Baird
- Mettler-Toledo price target raised to $1,400 from $1,350 at Wells Fargo
- Mettler-Toledo’s Balanced Risk/Reward Scenario Amid Conservative 2025 Outlook: Hold Rating Justified
- Mettler-Toledo Earnings Call: Strong Growth Amid Challenges
- Mettler-Toledo Faces Financial Risks Amid Climate Change and Stakeholder Pressures
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue